SI 613

Drug Profile

SI 613

Alternative Names: Hyaluronic acid/non-steroidal anti-inflammatory drug; Hyaluronic acid/NSAID; ONO 5704; SI-613

Latest Information Update: 29 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Seikagaku Corporation
  • Developer Ono Pharmaceutical; Seikagaku Corporation
  • Class Antirheumatics; Drug conjugates; Glycosaminoglycans; Nonsteroidal anti-inflammatories
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Osteoarthritis
  • Phase II Tendinitis

Most Recent Events

  • 28 Sep 2017 Phase-II clinical trials in Tendinitis in Japan (unspecified route)
  • 01 Sep 2017 Seikagaku Corporation and Ono Pharmaceutical reach a definitive agreement to co-promote and co-develop SI 613 for Osteoarthritis in Japan
  • 01 Aug 2017 Seikagaku Corporation initiates enrolment in a phase III trial for Osteoarthritis in Japan (JapicCTI-173678)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top